Neil Stahl, EVP Research and Development at REGENERON PHARMACEUTICALS, INC. (REGN), sold 15,955 shares at $947.34 ($15.2M) on 2024-02-07, disclosed to the SEC on 2024-02-08.
Open-market sale of $15.2M REGN by EVP Research and Development. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $947.34 | 100 | $95K | 0.6% |
| 2 | $948.69 | 1,894 | $1.8M | 11.8% |
| 3 | $948.69 | 1,894 | $1.8M | 11.8% |
| 4 | $949.45 | 601 | $571K | 3.8% |
| 5 | $949.45 | 601 | $571K | 3.8% |
| 6 | $950.43 | 3,127 |
| $3.0M |
| 19.6% |
| 7 | $950.43 | 3,127 | $3.0M | 19.6% |
| 8 | $951.49 | 1,237 | $1.2M | 7.8% |
| 9 | $951.49 | 1,237 | $1.2M | 7.8% |
| 10 | $952.49 | 1,059 | $1.0M | 6.7% |
| 11 | $952.49 | 1,059 | $1.0M | 6.7% |
| 12 | $953.00 | 19 | $18K | 0.1% |
| Total | $950.36 avg | 15,955 | $15.2M | 100% |
| Filing → |
| REGN | SELL | 2022-08-08 | $28.4M | — | Filing → |
| REGN | SELL | 2021-05-18 | $18.2M | — | Filing → |
| REGN | SELL | 2020-05-11 | $5.9M | — | Filing → |